Clinical Trial: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06921759) titled 'A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis' on April 04.

Brief Summary: The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis.

This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Atopic Hand and Foot Dermatitis

Intervention: DRUG: Lebrikizuma...